CBtru®, an innovative drug delivery solution

Formulating a highly lipophilic and poorly soluble crystalline molecule, such as cannabidiol (CBD), can be a complex task. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver. CBtru®, an innovative, patent-pending drug delivery solution, is making a new era in drug formulation possible—one that unlocks the true potential of highly lipophilic molecules. Enabling optimized bioavailability in solid oral dosage forms is paving the way for more patient-friendly delivery systems, such as tablets and capsules. This will help increase patient convenience and compliance, and elevate patient care worldwide.